On July 17, Innovent Biologics fell 3.45% in regular trading, trading at HK$89.85/share, with turnover of HK$499 million.
Within the Biotechnology sector where Innovent Biologics belongs, the overall sector performance was broadly weak. Among individual stocks, Akeso down 10.71%, 3SBio down 10.55%, SKB Bioscience down 5.42%, BeiGene down 2.25%, Remegen down 8.65%.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments